Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224433 | 0.83 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL29415755 | 0.83 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL19224432 | 0.83 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL19255775 | 0.83 | RIPK1 (0.73) | RIPK1 | |
| Eclitasertib SCHEMBL19207480 | 0.81 | RIPK1 (0.77) | RIPK1 | |
| Eclitasertib SCHEMBL19207477 | 0.81 | RIPK1 (0.77) | RIPK1 | |
| Eclitasertib SCHEMBL19224719 | 0.81 | RIPK1 (0.77) | RIPK1 | |
| SCHEMBL22736926 | 0.79 | RIPK1 (0.66) | RIPK1 | |
| SCHEMBL22737137 | 0.79 | RIPK1 (0.66) | RIPK1 | |
| SCHEMBL25330635 | 0.78 | RIPK1 (0.51) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233576-A1 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | GENZYME CORPORATION | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233576-A1 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.